as Alnylam Picks Inex s Platform Over Protiva s Despite Co-Authoring Study Supporting It in RNAi | GenomeWeb

Alnylam Pharmaceuticals said this week that it has obtained an option to exclusively license a liposomal-based drug-delivery technology from Inex Pharmaceuticals, even though that technology is at the center of a legal thicket that raises doubts about who actually owns the rights to license it.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.

In Science this week: global genetic diversity map, and more.